2016 Half-Year Results Information meeting, 12 September 2016
Table of contents 1. H1 2016 Results Jean-Yves SAMSON 2. The market in second-half 2016 Thierry CHAPUSOT 3. H2 2016 Outlook Dominique PAUTRAT 4. Conclusion Thierry CHAPUSOT 2 12 September 2016 2016 HALF-YEAR RESULTS
2016 Half-Year Results Financial results as at 30 June 2016 3 12 September 2016 2016 HALF-YEAR RESULTS
Financial results 2016 key figures Turnover (in € M) Net profit (in € M) +12.5% +13.1% 10.5 63.5 9.3 8.7 58.3 56.2 2014 2015 2016 2014 2015 2016 Net profit attributable to Net earnings per share Proforma following the share split by 5 equity holders of the parent (in € M) +8% +8% 10 9.3 0.67 8.7 0.62 0.57 2014 2015 2016 2014 2015 2016 4
Financial results H1 2016 turnover € millions 2016 2015 Change Q1 30.46 27.04 +12.65% Q2 33.07 29.15 +13.45% Total first half 63.53 56.19 +13.07% 5 12 September 2016 2016 HALF-YEAR RESULTS
Financial results Financial results Contribution to turnover Contribution to operating profit 6.7% 11.3% 7.4% 7.9% 11.9% 78% 76% The performance of our growth drivers, namely the Solutions for sanitary and medico- social establishments and Solutions for e-Health Divisions , confirms the suitability of the PHARMAGEST Group’s diversification strategy. Solutions for Pharmacy Division - Europe Solutions for medico-social establishments Division Solutions for e-Health Division FinTech Division 6
Financial results Financial results Income statement In € millions H1 2016 H1 2015 Change TURNOVER 63.53 56.19 +13.1% OPERATING PROFIT 15.61 14.04 +11.2% NET PROFIT 10.45 9.29 +12.5% NET PROFIT ATTRIBUTABLE TO 10.01 9.26 +8% OWNERS OF THE PARENT NET EARNINGS PER SHARE 0.67 0.62 +8% (in € ) 7 12 September 2016 2016 HALF-YEAR RESULTS
Financial results Financial results Balance sheet In € millions June 2016 Dec. 2015 June 2016 Dec. 2015 NON-CURRENT ASSETS 50.16 46.41 EQUITY CAPITAL 92.77 91.56 R&D 8.72 8.25 Of which group share 91.39 90.65 Goodwill 30.25 27.74 Other non-current assets 11.19 10.42 NON-CURRENT LIABILITIES 7.84 5.24 LT debts 3.78 1.10 Other non-current liabilities 4.06 4.14 CURRENT ASSETS 89.82 77.57 Accounts receivable 20.48 15.99 CURRENT LIABILITIES 39.37 27.19 Other current assets 7.09 6.45 ST debts 1.19 0.48 Cash 20.60 13.95 Trade accounts payable 8.62 6.70 Securities available for sale* 41.65 41.18 Other current liabilities 29.56 20.01 TOTAL 139.98 123.98 TOTAL 139.98 123.98 * And other financial assets 8 12 September 2016 2016 HALF-YEAR RESULTS
Financial results Summary cash flow table € millions Net cash 31/12/2015 (**) 54.89 Net cash provided by operating activities +11.81 Change in WCR +5.67 Operating investment (*) -2.20 Financial investments -2.71 Dividends -9.10 Loans +2.87 Other financial operations +0.48 Net cash 30/06/2016 (**) 61.71 (*) of which R&D at € 1,466 K 9 (**) of which securities available for sale
Stock market information Market capitalisation was € 360.08 million on 23 March 2016. It was € 409.70 million on 5 September 2016. Source: Boursorama 10 12 September 2016 2016 HALF-YEAR RESULTS
Solutions for Pharmacy Division - Europe - H1 2016 Pharmacy France H1 2016 turnover: down 1% to € 49.57 million Accounts for 78% of the Group's total turnover Although turnover fell by a slight 1% relative to the same period in 2015, driven down by the negative stage of the rental contracts cycle in the first half, recurrent turnover was up 2.7%. 11 12 September 2016 2016 HALF-YEAR RESULTS
Solutions for sanitary and medico-social establishments Care Homes - H1 2016 H1 2016 turnover: € 4.99 million, 52.96% growth Accounts for 7.85% of the Group's total turnover • The number of customer sites rose (our installed base now totals 1,475 care homes), including 136 new customers added in the first half, an increase of 26% year-on-year . • It is important to note the conclusion at the start of the year of two major hospital contracts for facilities with 500+ beds (in the gerontology and elderly residential care homes sector). The successful completion of these projects demonstrates our expertise and capacity to deliver complex projects.
Pharmaceutical Solutions for e-Health Division - H1 2016 companies H1 2016 turnover: € 4.71 million, 66.84% growth Accounts for 7.42% of the Group's total turnover This Division's expertise breaks down into four areas: Health software Collaborative Web Internet of Expert Hosting of applications Things systems Health Data for patient follow-up Creator of patient solutions 13
Fintech Division - H1 2016 H1 2016 turnover: € 4.25 million Accounts for 6.70% of the Group's total turnover Established in 2015, this Division includes the activities of our NANCEO subsidiary. After an encouraging first quarter ( € 1.68 million in turnover), Q2 confirms the Fintech Division's excellent performance with turnover totalling € 2.58 million. This new Division aims to quickly offer the use of its marketplace for the funding of goods and services beyond France, while at the same time developing international partnerships. 14 12 September 2016 2016 HALF-YEAR RESULTS
Outlook Market outlook in H2 2016 12 September 2016 2016 HALF-YEAR RESULTS 15
Market context 16 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Altogether now The French Pharmaceutical Unions Federation, the Fédération des Syndicats Pharmaceutiques de France , and the French Pharmaceutical Union have called on pharmacists to take part in a consultation on the future of their profession. The consultation was launched on 28 July. Action relayed on the LGPI portal with the agreement of the Presidents of both Unions 17 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Making the future The consultation aims to gather pharmacists' views on six key topics. New technologies in the Health insurance and Network organisation pharmacy supplementary health insurance Set-up and hygiene rules, agreement E-health, telemedicine, connected objects, grouping, closure, transfer, etc Internet, etc French national third-party payer agreement, prescription drugs, simplification of administrative procedures, etc Pharmacy business financials Pharmacist’s role Pharmacy team education and training Margin, fees, payments based on Consultations in the pharmacy, support, public health objectives (ROSP), services, PDA, delivery, compliance, Initial qualification and continous professional development (CDP), consultations in the pharmacy, etc therapeutic patient education, length of university degree, etc care, etc 18 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Making the future At the same time and given the position of pharmacies as key players in the healthcare chain, pharmacists have the opportunity to freely and openly express their views, make suggestions, and share their vision for the future of the sector. 10 practical suggestions from the pharmacists' union, the USPO 19 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Secure a commitment from the French government and the 1 health insurance system to reform pharmacies over the term of the agreement to: • Change the method of paying pharmacists to include the dispensing fee as part of a stepped negotiated budget according to margin; REGULATORY / • Strengthen the pharmacy network to prevent lack of coverage POLICY in some areas; • Enable the development of biosimilar and generic products by pharmacies; • Extend in-pharmacy consultations and payments based on public health objectives. 20 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Improve coordination between the members of the care team 2 and the pharmacist, in collaboration with other health professionals. E-NEPHRO renal screening 2013 2015 2011 2013 2016 2015 MSS operator to come (secure health messaging system) 21 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Organise relations between the city council and the hospital 3 and plan discharge with the patient's chosen pharmacy. E-NEPHRO renal screening 2013 2013 22 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Set up consultations and services to be offered by pharmacies, 4 particularly for vulnerable patients at home, meet a three-fold challenge: an ageing population, the shift towards ambulatory care, and the increase in chronic conditions. E-NEPHRO Patient follow-up 2005 renal screening programmes, advice sheets 2008 Interactive service, SST 2010 Posonet 2013 "36 more months at home" 2013 2011 2015 2016 23 12 September 2016 2016 HALF-YEAR RESULTS
Consultation on the future of the profession Prevention and screening: include pharmacies, especially in 5 vaccination, anti-smoking and addiction policy. E-NEPHRO 2007 renal screening Patient follow-up 2005 2013 programmes, advice sheets Screening and vaccination 2008 information campaign Partnerships with patient 2010 groups 2016 24 12 September 2016 2016 HALF-YEAR RESULTS
Recommend
More recommend
